Testicular Cancer and Male Fertility - A Meta-Analysis by Diogo Bernardo de Lacerda Queiroz e Almeida
  
 
 
 
 
 
Testicular Cancer and Male Fertility: A Meta-Analysis 
Diogo Bernardo de Lacerda Queiroz e Almeida 
 
 
 
Thesis Application to the Degree of Master 
Supervisor: Prof. Doctor Rosália Maria Pereira de Oliveira e Sá 
Assistant Professor at the Abel Salazar Institute of Biomedical Sciences, University of Porto. 
Co-supervisor: Prof. Doctor Mário Manuel da Silva Leite Sousa 
Full Professor at the Abel Salazar Institute of Biomedical Sciences, University of Porto. 
 
 
 
Instituto de Ciências Biomédicas Abel Salazar 
Integrated Master in Medicine 
 
Porto, 2016 
 
 
 ii 
 
  
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Again to my family and to Catarina, 
For shining an eternal light in my life 
 iv 
 
  
 v 
 
RESUMO 
OBJETIVO: O cancro testicular é das neoplasias diagnosticas em idade fértil com melhor 
prognóstico. No entanto, o impacto das sequelas do cancro testicular e seu tratamento no 
potencial reprodutivo masculino permanecem controversos. Desta forma, tivemos como objetivo 
avaliar e estimar o risco do cancro testicular e seu tratamento na função testicular. 
DESENHO: Foi realizada uma procura na PubMed utilizando palavras-chave tópico sobre o 
assunto. Os estudos foram selecionados de acordo com vários critérios. De seguida, foi realizada 
uma meta-análise usando um modelo de efeitos aleatórios, e foram utilizadas as seguintes 
medidas de consistência: I
2
, Q de Cochrane e estimativa de τ. 
RESULTADOS: Os pacientes incluídos encontravam-se em idade reprodutiva (29,20 ± 6,15) no 
momento do diagnóstico. A espermatogénese estava alterada antes do tratamento, com menor 
concentração de espermatozoides e motilidade. O tratamento não teve um impacto negativo na 
espermatogénese a longo prazo. Antes do tratamento, foi ainda observado um valor superior no 
dano genómico nos espermatozoides. Em relação ao controlo hormonal da espermatogénese, 
após tratamento verificou-se um aumento dos níveis das hormonas folículo-estimulante e 
luteinizante e uma diminuição dos níveis séricos de testosterona. 
CONCLUSÃO: Estudos que avaliam a função gonadal em doentes com cancro testicular têm 
sempre amostras limitadas e informação sobre o doente antes e após tratamento encontra-se em 
falta. A maioria destes doentes parece recuperar a sua capacidade reprodutiva e/ou são 
aconselhados a criopreservar esperma antes do tratamento. No entanto a recuperação 
imprevisível e o risco de transmitir uma patologia aos filhos são motivos de preocupação. No 
sentido de validar as nossas descobertas, outras investigações devem ser realizadas e avaliada a 
validação clínica dos resultados. 
PALAVRAS CHAVE: Cancro Testicular, Função Gonadal, Preservação da Fertilidade 
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ABSTRACT 
PURPOSE: Testicular cancer (TC) is one of the most treatable malignancies diagnosed at 
reproductive age. However, the adverse sequelae of TC and its treatment on future male 
reproductive potential remain controversial. Therefore we aimed to evaluate and estimate the risk 
of TC and its treatment on male gonadal function. 
DESIGN: A PubMed search was performed using topic keywords on the subject. Studies were 
included according several criteria. Afterwards, a meta-analysis using a random-effect model 
was conducted, and measures of consistency I
2
, Cochrane’s Q and estimation of τ were used. 
RESULTS: Patients included in this study were on reproductive age (29.20 ± 6.15) at diagnosis. 
Spermatogenesis was already affected before treatment, with patients showing decreased sperm 
concentration and motility. Therapy did not have a long-term negative influence on 
spermatogenesis. A significantly increase of male gamete genomic damage before treatment was 
also observed. Regarding the hormonal control of spermatogenesis it was found that serum of 
follicle-stimulating hormone and of luteinizing hormone levels increased after treatment, and 
serum testosterone levels decreased after treatment. 
CONCLUSION: Studies concerning gonadal function in TC patients were based on a limited 
number of patients, and lacked several information regarding pre-treatment and patients’ follow-
up post-treatment. Most TC patients seem to recover their ability to conceive and/or are 
counselled to preserve their fertility before treatment. Nonetheless fertility recovery is difficult to 
predict and the potential risk of transmitting an alteration to the offspring is of concern. In order 
to increase the validity of our findings future research should be conducted and clinical outcome 
significance evaluated.    
KEYWORDS: Testicular Cancer, Gonadal Function, Fertility Preservation.  
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INTRODUCTION 
In recent years, there has been an increase in the incidence of testicular cancer (TC) (1). 
Although most TC patients will be cured, thousands will still die every year around the 
world (1), and many challenges remain (2). TC constitutes a group of tumours, of which 
95% are germ cell tumours (3). These can be categorized in seminoma and 
nonseminoma (4).  TC is the most common solid malignancy among men between 15 
and 35 years (5). An increased risk of TC is associated with cryptorchidism (6), 
personal (7) and family (8-10) history of TC, testicular microlithiasis (11, 12), diet (13), 
environmental endocrine disrupting chemicals (14, 15) and genetic factors (16), such as 
isochromosome i(12)p (17) and mutations on KIT and RAS genes (18), among others. 
Although subfertile men also have a higher incidence of TC (19), TC can also cause 
sub/infertility (20). In fact, there is an overwhelming body of evidence that TC patients 
have lower fertility status, with up to 52% of patients being oligozoospermic and 10% 
being azoospermic at diagnosis (21). Moreover, there is evidence that TC treatment can 
diminish even more the fertility potential of these patients (22). Despite this, and unless 
a bilateral radical orchiectomy is performed, data seem to suggest that: a) these men 
may convalesce sperm production after orchiectomy (23), and b) when these patients 
need to resort to chemotherapy (CT) and radiotherapy (RT), the impact of these 
treatments on spermatogenesis appears to be augmented (20, 23), with those resulting 
from CT being more injurious (20, 23). Therefore, long-term sequelae on reproductive 
health and fertility are of great concern. The treatment-related toxicity over 
spermatogenesis may instigate testicular failure, and an abnormal hormonal status. This 
is mainly due to proliferating spermatogonial stem cells and their similarity to swiftly 
dividing malignant cells to damage during treatment. The time required to recover 
testicular function also remains controversial. Due to the sensitiveness of germinal 
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epithelium to TC and its treatment, and given that the influence of TC and of treatments 
on male fertility remains controversial, we have considered relevant to perform an 
evaluation of the studies that have determined the former associations. Knowledge of 
the association between testicular cancer and patients’ semen parameters, hormonal 
levels and sperm integrity is of clinical significance as it will enable physicians to take 
an informed preventive strategy regarding fertility. To the best of our knowledge, there 
is no meta-analysis on this specific subject. As such, we conducted this meta-analysis to 
estimate the magnitude of the influence of TC on male reproductive potential before 
and/or after treatment. Because of studies’ scarcity, both retrospective and prospective 
studies were included in this meta-analysis. No comparisons were made with the 
condition of other cancer patients. 
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METHODS 
Search Strategies 
The search for articles consisted of three initial searches in the PubMed database using 
the following search words: testicular cancer AND (hormonal profile OR semen 
parameters OR sexual function). The searches wielded 31, 81 and 319 results, 
respectively. An additional search was conducted using the words (chemotherapy AND 
male reproduction) which exerted 22425 results. After filtering for clinical trials and 
human species, the results were reduced to 1872. All articles’ abstracts were read and if 
the content matched the study design for any parameters of sexual fertility in TC 
patients (either before and/or after cancer treatment), the article was fully analysed. 
Articles were included if they provided the necessary data to conduct the meta-analysis. 
The reference lists of manuscripts of key journals were hand searched for additional 
articles. A total of 42 articles from 1984 to April 2016 were included in this meta-
analysis. We did not include unpublished data, or articles written in languages other 
than English. Figure 1 depicts the search process.  
Testicular Cancer 
AND 
Hormonal Profile 
 
Testicular Cancer 
AND 
Semen Parameters 
 
Testicular Cancer 
AND 
Sexual Function 
 
Chemotherapy 
AND 
Male Reproduction 
 
References 
Search 
  
 
  
 
  
    
 
 
   22425 Results   
       
   
Filters: 
-Humans 
-Clinical trials 
  
       
81 Results  31 Results  319 Results  1872 Results   
             
43 Results With The Appropriate Data 
Fig 1 - Study Selection Flowchart. 
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Statistical analysis 
When the studies presented information for the different types of TC but not for the TC 
group as a whole, this group was recreated using the summary data of the different sub-
groups. 
The meta-analysis was performed under a random effect model except when 
estimated τ was zero (24). The choice of using random effect was due because most 
studies included were observational meaning that different possible factors could 
influence the assessed measures, making this model the best for the present study (25). 
Heterogeneity and dispersion between studies were assessed with Cochran’s Q-
test and I
2
, respectively.  However, their values were used only to speculate on factors 
that could justify the differences observed. 
Statistical analyses were conducted using Microsoft Office Excel and the ESCI 
software (26). Two-tailed t tests were used to assess possible differences (assuming 
equal variances when differences were calculated within the same studies and not 
assuming equal variances when differences were calculated with different studies) and a 
P value less than 0.05 was chosen as the cut-off to consider a statistically significant 
difference. Information is presented as mean ± standard deviation, or mean (confidence 
interval 95%). 
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RESULTS 
Studies’ selection  
Table 1 describes the selected studies. Forty-three studies were included in the present 
meta-analisys, which enrolled 7511 patients suffering from TC. Among these, 710 and 
654 men were identified to have seminoma and nonseminoma, respectively. 2531 were 
recruited as controls. 
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Table 1. Characteristics of the studies included. 
Publication 
year 
Reference Type of study Time (months) Country Sample size 
(Patients/Controls) 
Treatment Mean age Comments Parameters evaluated 
included in the 
present meta-analysis 
1984 (27) Prospective At diagnosis  USA TC: 14 Orchiectomy TC: 30 NA V, SC 
1991 (28) Retrospective At diagnosis USA TC: 60 
Controls: 20 
Prophylactic semen cryopreservation NA Orchiectomy not defined V, SC, TM 
1992 (29) Prospective At diagnosis USA TC: 10 BEP NA Orchiectomy not defined LH, TT 
1994 (30) Prospective At diagnosis 
3, 6, 12, 18, 30 
USA T0: 8 
T3: 4 
T6: 4 
T12: 4 
T18: 2 
T30: 1 
Orchiectomy and RT TC: 32.9 ± 5.6 Seminoma SC, TM, VIT, SM 
1995 (31) Retrospective At diagnosis USA TC: 33 
Seminoma: 9 
Nonseminoma: 24 
Controls: 30 
Prophylactic semen cryopreservation TC: 26.0 ± 5.8 
Controls: 31.4 ± 7.6 
Separated by type of cancer, has 
stages 
Orchiectomy not defined 
V 
1997 (32) Retrospective At diagnosis Israel TC: 66 
Seminoma: 32 
Nonseminoma: 22 
Prophylactic semen cryopreservation 
Orchiectomy in some patients 
TC: 29.6 Separated by type of cancer FSH, LH, TT 
1997 (33) Prospective At diagnosis  
3, 6, 12, 24, > 24 
Germany Transversal: 232 
Longitudinal: 
T0: 51 
T6: 38 
T12: 38 
T24: 41 
T>24: 37 
Orchiectomy and CT (different treatments) TC: 31.5 ± 7.8 Has a Longitudinal and 
Transversal Study 
FSH, LH, TT 
1998 (34) Retrospective 18 Greece TC: 16 
Controls: 52 
RT TC: 30.4 ± 4.8 
Controls: 30.4 ± 4.8 
NA V, SC, TM, SM 
1999 (35) Prospective At diagnosis Greece TC: 12 
Controls: 60 
Orchiectomy NA Seminoma V, SC, TM, SM 
2001 (36) Prospective At diagnosis USA TC: 20 
Controls: 12 
Prophylactic semen cryopreservation NA NA V, SC, TM 
2003 (37) Retrospective At diagnosis Italy TC: 222 
Seminoma: 118 
Nonseminoma: 104 
Prophylactic semen cryopreservation Orchiectomy TC: 28.8 ± 5.6 
Controls: NA 
Separated by type of cancer 
No azoospermic patients 
V, SC, TSC, PM, SM 
2003 (38) Retrospective > 24 Norway TC: 1183 
Surg: 251 
RT: 515 
CT1: 373 
CT2: 96 
Controls: 200 
Surgery, RT, cisplatin (with or without surg and RT) Surg: 42 ± 8.9 
RT: 46 ± 8.3 
CT1: 42 ± 8.7 
CT2: 38 ± 9.2 
Separated by type of treatment LH, TT 
2004 (39) Prospective At diagnosis Germany TC: 16  NA NA V, S, TSC, SM 
2004 (40) Retrospective At diagnosis USA TC: 32 Prophylactic semen cryopreservation NA Orchiectomy not defined SC, SM, SM 
2004 (41) Retrospective > 24 Japan TC: 10 
Seminoma: 5 
Nonseminoma: 5 
CT (High dose) Azoospermic: 36.2 ± 6.53 
Non-azoospermic: 28.2 ± 
8.76 
Separates cases depending on 
azoospermia 
SC, TM 
FSH, LH, TT 
2004 (42) Prospective At diagnosis 
> 24 
France TC: 14 BEP and/or RT TC: 35.4 ± 6.4 Orchiectomy not defined 
All over 18 years 
SC, PM, SM 
2006 (43) Retrospective At diagnosis Taiwan TC: 10 Prophylactic semen cryopreservation TC: 26.3 ± 8.5 
Controls: NA 
Orchiectomy not defined SC, PM 
2006 (44) Prospective At diagnosis 
3, 6, 9, 12, 24 
Italy T0: 166/ 
T3: 67 
T6: 53 
T9: 74 
T12: 106 
T24: 86 
BEP or RT CH: 26.7 ± 4.4 
RT: 29.8 ± 4.9 
Separated by type of cancer 
No azoospermic patients at 
diagnosis 
Orchiectomy not defined 
V, SC, TSC, PM, SM 
2007 (45) Retrospective At diagnosis Canada TC: 40 Prophylactic semen cryopreservation NA Orchiectomy not defined 
SM not used due to SD value (0) 
Some pediatric patients 
V, SC, PM 
2008 (46) Retrospective At diagnosis Spain TC: 37 
Seminoma: 26 
Nonseminoma: 11 
Prophylactic semen cryopreservation NA Separated by type of cancer 
Orchiectomy not defined 
SCS 
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2008 (47) Prospective At diagnosis Brasil TC: 48 
Seminoma: 19 
Nonseminoma: 29 
Controls: 50 
Prophylactic semen cryopreservation Seminoma: 26.1 ± 5.1 
Nonseminoma: 27 ± 4.8 
Controls: 28.9 ± 6.4 
 
All patients achieved paternity 
Separated by type of cancer 
Orchiectomy not defined 
V, SC, PM, SM 
2009 (48) Retrospective At diagnosis Brasil TC: 55 Prophylactic semen cryopreservation TC: 28.9 ± 0.9 Orchiectomy not defined SC, PM, TM, SM 
2009 (49) Retrospective At diagnosis Czeck 
Republic 
TC: 270 Prophylactic semen cryopreservation NA NA SC 
2009 (50) Retrospective At diagnosis France TC: 33 Prophylactic semen cryopreservation NA Only volume used because of 
possible patient repetition with 
Rives et al 
V 
2009 (51) Prospective At diagnosis Canada? TC: 39 
Controls: 20 
Prophylactic semen cryopreservation TC: 30.7 ± 11.9 
Controls: 33.7 ± 4.8 
Orchiectomy not defined SC, PM, SCS 
2010 (52) Prospective At diagnosis Brasil TC: 100 
Seminoma: 37 
Nonseminoma: 63 
Prophylactic semen cryopreservation Seminoma: 30.4 ± 6.4 
Nonseminoma: 25.1 ± 5.1 
 
Has 3 cases of bilateral testicular 
cancer and 2 of extra-gonadal 
Orchiectomy not defined 
Separated by type of cancer 
V, SC, PM, SM 
2011 (53) Retrospective At diagnosis Israel TC: 43 Prophylactic semen cryopreservation TC: 26.0 ± 7.0 Orchiectomy not defined V, SC, PM, SM 
2012 (54) Retrospective > 24 Germany TC: 238 Various TC: 38.7 ± 9.4 Separated by type of cancer FSH, LH, TT 
2012 (55) Retrospective At diagnosis France TC: 1149 Prophylactic semen cryopreservation TC: 29.7 ± 6.57 Some with orchiectomy 
Compares different groups 
before and after orchiectomy 
SC, TSC, PM 
2012 (56) Prospective > 24 Turkey TC: 27 BEP TC: 34.0 ± 8.9 NA FSH, LH, TT 
2013 (57) Retrospective At diagnosis Israel TC: 17  Prophylactic semen cryopreservation NA Orchiectomy not defined SC, TM 
FSH 
2013 (58) Prospective At diagnosis  
3, 6, 12, 24 
 
France TC: 127 
3 months: 106; 6 months: 113; 12 
months: 103; 24 months: 91 
Controls: 257 
BEP or RT TC: 30.9 ± 4.9 Separated by type of cancer V, SC, TSC, PM, VIT, 
SCS 
2013 (59) Retrospective At diagnosis 
> 24 
China TC: 6 Prophylactic semen cryopreservation, after treatment 
(CH or RT) 
TC: 27.5 ± 6.8 Orchiectomy not defined V, SC, TM 
2013 (60) Retrospective At diagnosis Italy TC: 150 
Seminoma: 76 
Nonseminoma: 14 
Prophylactic semen cryopreservation 
Orchiectomy in some patients 
NA Separated by type of cancer V, TSC, PM, VIT 
2013 (61) Prospective At diagnosis  
6, 12, 18, 24, 36 
Italy TC: 261 
Seminoma: 154 
Nonseminoma: 107 
BEP or RT TC: 27.9 ± 0.6 Separated by type of cancer SC, PM, SM 
FSH, LH, TT 
2013 (62) Retrospective At diagnosis USA TC: 165 
Controls: 104 
Prophylactic semen cryopreservation NA Used motility stimulants and as 
such TM was excluded 
No azoospermic 
TSC 
2013 (63) Retrospective At diagnosis Australia TC: 37 
Controls: 35 
Prophylactic semen cryopreservation TC: 27.5 Orchiectomy not defined. V, SC, TM, SCS 
2013 (64) Prospective At diagnosis Japan TC: 49 Orchiectomy TC: 30.6 ± 5.8 NA V, SC, TM 
2013 (65) Prospective At diagnosis Spain TC: 37 
Seminoma: 15 
Nonseminoma: 22 
Controls: 35 
 TC: 28.4 ± 7.68 
Seminoma: 31.38 ± 7.95 
Nonseminoma: 26.4 ± 7.42 
Controls: 30.26 ± 6.9 
Separated by type of cancer TSC, PM, TM, SM, 
FSH, LH, TT 
2015 (66) Retrospective At diagnosis South 
Korea 
TC: 31 Prophylactic semen cryopreservation TC: 33.4 ± 6.0 Orchiectomy not defined V, SC, PM, SM, VIT 
2015 (67) Prospective At diagnosis 
3, 6, 9, 12, 24 
Italy T0: 139 
T3: 59 
T6: 54 
T9: 60 
T12: 75 
T24: 75 
CH or RT NA Some patients with orchiectomy 
at diagnosis 
TSC, TM, SM, SCS 
2015 (68) Retrospective At diagnosis Japan TC: 7 Orchiectomy TC: 36.3 ± 9.1 Only seminoma V, SC, TM  
2016 (69) Retrospective At diagnosis France TC: 2315 
Controls: 1656 
Prophylactic semen cryopreservation  Most before orchiectomy V, SC, TSC, PM, SM  
BEP, Bleomycin + Etoposide + Cisplatin; CT, chemotherapy;  FSH, follicle-stimulating hormone; LH, luteinizing hormone; NA, not available; PM, sperm progressive motility; RT, radiotherapy; SC, sperm concentration; SCS, sperm chromatin structure; SM, sperm morphology; 
Surg, surgery; TT, total testosterone; TC, testicular cancer; TM, sperm total motility; TSC, total sperm concentration; V, sperm volume; VIT, sperm vitality. 
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This meta-analysis was implemented to evaluate the association between TC and male infertility. 
To do this, patients’ characteristics, hormonal status or semen features before and/or after 
treatment were registered. Both retrospective and prospective studies were included. Studies 
were excluded if there was reason to believe that some parameter would be skewed, if there was 
the risk of patient repetition between studies or if they did not investigate the outcomes assessed 
in the present meta-analysis.  Data was extracted manually, independently, and in duplicate by 
two authors (DQA and RS). 
The variables collected from the studies were: country (name), pathology (testicular and 
if available seminoma and nonseminoma), time at evaluation (in months, 0 being after diagnosis 
and eventually orchiectomy but before other treatments, and then, months after treatment), status 
of orchiectomy at evaluation (prior, after or unknown), number of patients, type of treatment and 
dose if available, age at time of evaluation, sperm concentration (SC; 10
6
/mL), total sperm 
concentration (TSC; 10
6
),  semen volume (V; mL), sperm progressive motility (PM; %), sperm 
total motility (TM; %), sperm vitality (VIT; %), sperm morphology (SM; %), sperm chromatin 
structure (SCS; %), follicle stimulating hormone (FSH; IU/L), luteinizing hormone (LH; IU/L), 
and total testosterone (TT, nmol/L). 
Effects on patients’ characteristics 
Regarding age, patients suffering from TC and selected for this study (n = 7511) were within the 
expected age interval (5) as they presented a mean age of 29.20 ± 6.15 years old (assessed with 
2405 patients). Of these, patients with seminoma (n = 710) presented a statistically increased (p 
< 0.0001) mean age (30.17 ± 5.70 assessed with 308 patients) than patients with nonseminoma 
(n = 654; 26.32 ± 5.32 assessed with 313 patients).   
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Effects on sperm characteristics of patients 
Sperm characteristics are directly related to male fertility potential and are both commonly 
associated to sperm ability to successfully fertilize an oocyte and to pregnancy rates (70).  TC 
appears to display a more negative effect on semen than other cancers (21). The results on the 
influence of TC on the seminal parameters are reported in Table 2. 
For seminal volume, before treatment were analysed 21 studies (n = 3529), and 9 for 
controls (n = 2172). Before treatment, 7 studies were considered to determine the difference 
between seminoma (n = 424) and nonseminoma (n = 364).  After treatment, 3 studies (n = 183) 
that assessed V after 12 months were included. 2 studies assessed V for 24 months. No 
alterations are observed in patients suffering from TC even when considering different 
histopathological groups. 
Concerning concentration, both SC and TSC were studied. Although no difference is 
observed in SC before and after treatment, a statistically significant lower value (p < 0.0001) of 
SC both before and after treatment compared with control groups is observed on TC (28 studies 
before treatment, n=5167; 9 studies with controls, n=2162; 6 studies after treatment > 12 months, 
n=468). Regarding the histopathological groups of TC (6 studies), SC is statistically significantly 
inferior (p < 0.0001) in nonseminoma patients (n = 480) compared to seminoma patients (n = 
446). After treatment, prospective studies show a statistically significant decrease (p < 0.0001) 
on SC in the first 3 months. SC then remains stable up to 12 months. However, it is also detected 
a statistically significant increase (p < 0.0001) from this period until one year later. As far as for 
TSC evaluation this was statistically significantly higher (p =0.0014) after treatment (3 studies; n 
= 252) in relation to the time of diagnosis (10 studies; n = 4473). Still, both TSC values at 
diagnosis and after treatment were statistically significantly lower than the corresponding control 
group (3 studies; n = 2017). Before treatment, patients experiencing seminoma (n =259) do not 
present any difference on TSC from the ones experiencing nonseminoma (n = 248). Prospective 
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studies show a statistically significant lower (p < 0.0001) TSC up to 12 months after treatment. 
Though, with a trivial rise noticed from 3 to 6 months and then with a statistically significant 
increase (p < 0.0001) from 6 to 12 months, returning to values similar at diagnosis after 24 
months (p < 0.0001). 
With reference to motility, when analysing patients with TC no differences are observed 
both for PM (n = 4790) and TM (n =462), either before and after treatment. Nevertheless, both 
values are statistically significantly decreased comparing to controls (PM: n = 1983, p=0.0016; 
TM: n= 179; p=0.0164).  Seminoma patients (7 studies; n =522) present a statistically significant 
higher (p =0.0033) PM than nonseminoma ones (n = 494). Prospective studies (3 studies; n = 
191) demonstrate that PM statistically significantly decreases (p < 0.0001) from diagnosis up to 
3 months after treatment but from 6 to 12 months after treatment it statistically significantly 
increases (p < 0.0001) recovering to diagnosis’ values. 
For the parameter VIT, no differences are seen between seminoma (n = 146) and 
nonseminoma (n = 73) patients. Data for controls and for patients after treatment were not 
available. 
Regarding morphology, since diverse authors use different criteria, studies were divide 
according to strict or non-strict analyses. When non-strict criteria are used to classify normal SM 
(nsSM), sperm from seminoma (n = 213) and nonseminoma (n = 175) patients seem to display 
equal rates of normal morphology. Data for controls and for patients after treatment were not 
available. However, using strict criteria (sSM) TC patients (n = 725) have similar rates as 
controls (n = 162). Considering the two histopathological groups of TC, nonseminoma (246) has 
statistically significantly lower (p =0.0200) sSM than the seminoma (n = 163) one. 
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Table 2. Seminal parameters in testicular cancer patients. 
 At diagnosis, before treatment  After treatment  Controls 
SC 
10
6
/mL Ref. 
Mean 
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
(27) 
42.14 
(10.28, 73.99) 
0.98 
 
 
        
 
(28) 
26.70 
(21.30, 32.10) 
4.60 
 
 
     (28) 
73.20 
(58.76, 87.64) 
10.94 
 
(30) 
53.80 
(12.42, 95.18) 
0.72 
 
 
        
 
   
  
     (34) 
79.90 
(72.02, 87.78) 
12.07 
 
(35) 
23.80 
(9.95, 37.65) 
2.91 
 
 
     (35) 
77.40 
(70.24, 84.56) 
12.18 
 
(36) 
29.50 
(18.83, 40.17) 
3.44 
 
      (36) 
118.00 
(86.31, 149.69) 
7.47 
 
(37) 
30.20 
(25.93, 34.47) 
4.83 
 
         
 
(39) 
18.70 
(6.82, 30.58) 
3.22 
 
 
        
 
(40) 
45.20 
(28.07, 62.33) 
2.15 
 
 
        
 
   
  
(41) 
21.20 
(4.46, 37.94) 
15.58 
 
    
 
(42) 
36.60 
(13.04, 60.16) 
1.53 
 
 
(42) 
17.20 
(11.59, 22.81) 
17.56 
 
    
 
(43) 
41.80 
(21.21, 62.37) 
1.95 
 
 
        
 
(44) 
31.32 
(26.69, 35.95) 
4.76 
 
 
(44) 
46.36 
(38.16, 54.56) 
17.09 
 
    
 
(45) 
38.40 
(28.07, 48.73) 
3.44 
 
 
        
 
(47) 
24.80 
(18.45, 31.14) 
4.39 
 
 
     (47) 
78.10 
(63.21, 92.99) 
10.71 
 
(48) 
26.10 
(19.68, 32.52) 
4.37 
 
 
        
 
(49) 
17.20 
(14.64, 19.76) 
5.12 
 
 
        
 
(51) 
34.60 
(26.30, 42.90) 
3.93 
 
 
     (51) 
66.90 
(63.76, 70.04) 
12.61 
 
(52) 
18.76 
(14.08, 23.43) 
4.75 
 
 
        
 
(53) 
38.40 
(29.26, 47.54) 
3.72 
 
 
        
 
(55) 
26.18 
(24.34, 28.02) 
5.20 
 
 
        
 
(57) 
38.40 
(18.71, 58.09) 
1.90 
 
 
        
 
(58) 
31.34 
(25.72, 36.96) 
4.54 
 
 (58) 
34.58 
(27.71, 41.46) 
17.32 
 
 (58) 
98.67 
(87.50, 109.84) 
11.46 
 
(59) 
20.00 
(4.62, 35.38) 
3.04 
 
 (59) 
2.33 
(-0.91, 5.58) 
17.80 
 
    
 
(61) 
38.39 
(33.15, 43.63) 
4.62 
 
 
(61) 
46.64 
(28.81, 64.46) 
14.65 
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(63) 
22.90 
(13.00, 32.80) 
3.55 
 
 
     (63) 
56.63 
(38.44, 74.82) 
10.00 
 
(64) 
34.60 
(26.41, 42.79) 
3.94 
 
 
        
 
(66) 
25.70 
(19.06, 32.24) 
4.35 
 
 
        
 
(68) 
15.29 
(-0.48, 31.05) 
2.80 
 
 
        
 
(69) 
36.10 
(34.12, 38.08) 
5.20 
 
       
98.49 
(94.94, 102.03) 
12.56 
 
 
28.29 
(27.36, 29.22) 
 
 
  
27.48 
(11.52, 43.45) 
 
 
  
82.04 
(70.01, 94.06) 
 
 
 Q: 210.12; I2: 87.15%; T: 6.95    Q: 190.27; I2: 97.37%; T: 19.27    Q: 207.23; I2: 96.14%; T: 17.21  
 
 Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(30) 53.80 (12.42, 95.18) 2.40        
(35) 23.80 (9.95, 37.65) 10.01        
(37) 36.50 (29.61, 43.39) 14.85  23.09 (18.68, 27.51) 17.68  -13.41 (-21.79, -5.02) 23.42 
 
(44) 34.40 (27.43, 41.37) 14.80  27.20 (21.66, 32.74) 16.68  -7.20 (-16.51, 2.11) 19.05 
 
(47) 31.20 (18.57, 43.83) 10.44  20.60 (13.87, 27.33) 15.68  -10.60 (-23.33, 2.13) 10.59 
 
(52) 25.98 (15.14, 36.82) 11.52  14.46 (10.71, 18.21) 18.25  -11.52 (-20.97, -2.07) 18.70 
 
(58) 34.84 (26.12, 43.57) 13.22  27.01 (20.60, 33.42) 15.85  -7.84 (-18.92, 3.24) 13.52 
 
(61) 46.00 (37.08, 54.92) 12.99  33.10 (26.78, 39.42) 15.86  -12.90 (-23.47, -2.33) 14.72 
 
(68) 15.29 (-0.48, 31.05) 9.79        
 32.51 (26.82, 38.20)   24.02 (18.43, 29.60)   -10.75 (-14.78, -6.71)  
 
 Q: 22.45; I2: 64.37%; T: 6.68  Q:34.50; I2: 85.50%; T: 6.40  Q:1.41; I2: 0.00%; T: 0  
 
Time after treatment 
 0-3 months  0-6 months  3-6 months  0-12 months  6-12 months  0-24 months  12-24 months 
Ref. 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
(30) 
-34.10 
(16.25, 21.96) 
0.87  
-41.10  
(-98.44, 16.24) 
1.31  
-7.00  
(-42.13, 28.13) 
1.47  
49.68  
(-61.77, 161.12) 
0.20  
90.78  
(-67.28, 248.83) 
0.26       
(44) 
-24.25 
(14.91, 17.68) 
42.39  
-23.58  
(-32.00, -15.16) 
33.30  
0.67  
(-4.05, 5.38) 
53.23  
-9.91  
(-16.64, -3.18) 
43.12  
13.67  
(7.05, 20.29) 
39.03  
15.04  
(6.37, 23.71) 
40.04  
24.95  
(16.19, 33.71) 
40.50 
(58) 
-24.62 
(18.13, 26.88) 
56.74  
-21.73  
(-28.95, -14.51) 
40.80  
2.89  
(-2.20, 7.98) 
45.30  
-12.46  
(-19.95, -4.97) 
34.80  
9.27  
(2.90, 15.65) 
40.10  
3.25  
(-5.53, 12.02) 
39.61  
15.70  
(7.60, 23.81) 
45.89 
(61)    
-12.04  
(-22.35, -1.74) 
24.62     
-11.29  
(-20.72, -1.85) 
21.85  
0.76  
(-11.10, 12.61) 
20.57  
9.00  
(-6.05, 24.06) 
20.34  
20.29  
(4.14, 36.44) 
13.61 
 
-24.55 
(-29.43, -19.66) 
  
-20.21  
(-26.02, -14.41) 
  
1.56  
(-1.84, 4.97) 
  
-10.98  
(-15.38, -6.58) 
  
9.45  
(2.97, 15.94) 
  
9.14  
(1.23, 17.05) 
  
20.07  
(13.93, 26.21) 
 
  Q:0.13; I2: 0.00%; T: 0  Q:3.87; I2: 22.50%; T: 2.84  Q:0.76; I2: 0.00%; T: 0  Q: 1.72; I2: 0.00%; T: 0  Q: 5.16; I2: 41.86%; T: 4.10  Q: 3.55; I2: 43.63%; T: 4.61  Q: 2.34; I2: 14.38%; T: 2.13 
 
 At diagnosis, before treatment  After treatment  Controls 
TSC 
106 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
(37) 
99.90 
(85.59, 114.21) 
10.88 
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(39) 
48.70 
(20.46, 76.94) 
9.51 
 
         
 
(44) 
102.08 
(86.94, 117.23) 
10.81 
 
 (44) 
124.45 
(105.09, 143.80) 
46.14 
 
    
 
(55) 
92.82 
(85.83, 99.81) 
11.42 
 
         
 
(58) 
115.31 
(90.13, 140.48) 
9.65 
 
 (58) 
126.93 
(97.59, 156.27) 
20.05 
 
 (58) 
361.95 
(319.79, 404.11) 
32.74 
 
(60) 
44.89 
(30.73, 59.04) 
10.90 
 
         
 
(62) 
65.70 
(49.38, 82.03) 
10.69 
 
      (62) 
185.80 
(151.34, 220.26) 
33.24 
 
(65) 
115.13 
(40.25, 190.00) 
4.39 
 
         
 
(67) 
132.30 
(112.71, 151.89) 
10.33 
 
 (67) 
141.50 
(118.84, 164.16) 
33.81 
 
    
 
(69) 
127.00 
(119.91, 134.09) 
11.42 
 
      (69) 
364.64 
(348.69, 380.58) 
34.03 
 
 
93.40 
(74.55, 112.25) 
 
 
  
130.71 
(117.75, 143.67) 
 
 
  
335.64 
(190.27, 418.36) 
 
 
 Q: 163.47; I2: 94.49%; T: 28.23    Q: 1.38; I2: 0.00%; T: 0    Q: 88.60; I2: 97.74%; T: 99.42  
 
 Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(37) 122.00 (99.87, 144.13) 25.43  74.73 (58.28, 91.19) 43.42  -47.27 (-75.30, -19.23) 27.08 
 
(44) 115.90 (93.47, 138.33) 25.29  83.60 (65.07, 102.13) 36.10  -32.30 (-62.60, -2.01) 26.63 
 
(58) 121.54 (85.40, 157.69) 23.50  107.59 (73.26, 141.91) 12.04  -13.96 (-63.92, 36.01) 22.15 
 
(60) 34.00 (17.74, 50.26) 25.89  94.50 (49.86, 139.14) 8.44  60.50 (18.82, 102.18) 24.15 
 
 97.56 (47.05, 148.07)   82.92 (71.94, 93.90)   -9.88 (-54.98, 35.22)  
 
 Q: 61.15; I2: 95.09%; T: 49.98  Q:3.36; I2: 10.75%; T: 4.20  Q:19.11; I2: 84.30%; T: 41.90  
 
Time after treatment 
  0-3 months  0-6 months  3-6 months  0-12 months  6-12 months  0-24 months  12-24 months 
 
Ref. 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 (44) 
-79.21 
(-103.91,  
-54.51) 
58.14  
-77.58  
(-105.1, -50.06) 
59.97  
1.63  
(-13.74, 17.01) 
72.56  
-33.99  
(-56.45, -11.53) 
48.78  
43.59  
(20.61, 66.57) 
61.41  
22.36  
(-2.76, 47.48) 
48.27  
56.35 
(32.18, 80.53) 
45.24 
 (58) 
-90.58 
(-119.68,  
-61.47) 
41.86  
-76.68  
(-110.35, -43.01) 
40.03  
13.90  
(-10.98, 38.78) 
27.44  
-46.96  
(-79.36, -14.56) 
23.49  
29.72  
(0.79, 58.65) 
38.59  
11.62  
(-26.90, 50.15) 
20.55  
58.59  
(24.92, 92.25) 
23.33 
 (67)          
-37.80 
(-67.63, -7.97) 
27.73     
9.20  
(-22.08, 40.48) 
31.18  
47.00  
(17.94, 76.06) 
31.43 
  -83.97 
(-102.70, -
65.24) 
  
-77.22  
(-98.41, -56.03) 
  
5.00  
(-7.96, 17.96) 
  
-38.09  
(-53.71, -22.48) 
  
38.24  
(20.37, 56.11) 
  
16.05  
(-1.32, 33.42) 
  
53.93  
(37.78, 70.09) 
 
  Q:0.34; I2: 0.00%; T: 0  Q:0.00; I2: 22.50%; T: 2.84  Q:0.68; I2: 0.00%; T: 0  Q: 0.42; I2: 0.00%; T: 0  Q: 0.55; I2: 0.00%; T: 0  Q: 0.48; I2: 0.00%; T: 0  Q: 0.34; I2: 0.00%; T: 0 
. 
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 At diagnosis, before treatment  After treatment  Controls 
V 
mL Ref. 
Mean 
(95% CI) 
Weight % 
 
 Ref. 
Mean  
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
(95% CI) 
Weight 
% 
 
(27) 
3.29 
(2.07, 4.52) 2.13 
 
 
    
 
   
 
(28) 
3.00 
(2.60, 3.40) 5.40 
 
 
    
 
(28) 
3.00 
(2.58, 3.42) 
11.60 
 
(31) 
3.08 
(2.47, 3.68) 4.26 
 
 
    
 
(31) 
2.90 
(3.38, 3.42) 
10.17 
 
 
 
 
  
 
 
  
 
(34) 
3.70 
(3.23, 4.17) 
10.68 
 
(35) 
4.10 
(2.96, 5.24) 2.40 
 
 
 
 
  
 
(35) 
3.80 
(3.34, 4.27) 
10.77 
 
(36) 
3.50 
(3.08, 3.92) 
5.40 
 
      (36) 
2.80 
(1.92, 3.68) 
6.97 
 
(37) 
3.40 
(3.18, 3.62) 
6.33 
 
         
 
(39) 
2.80 
(2.21, 3.39) 
4.52 
 
 
 
 
      
 
(44) 
3.43 
(3.18, 3.62) 
6.23 
 
 
(44) 
2.99 
(2.70, 3.27) 
36.59 
 
    
 
(45) 
3.00 
(2.39, 3.61) 
4.24 
 
 
 
 
      
 
(47) 
3.00 
(2.53, 3.47) 
4.99 
 
 
 
 
   (47) 
3.30 
(2.93, 3.67) 
12.01 
 
(50) 
2.99 
(2.46, 3.52) 
4.70 
 
 
 
 
  
 
   
 
(52) 
2.60 
(2.33, 2.87) 
6.12 
 
 
 
 
  
 
   
 
(53) 
3.20 
(2.71, 3.69) 
4.88 
 
 
 
 
  
 
   
 
(58) 
3.60 
(3.31, 3.89) 
6.00 
 
 
(58) 
3.69 
(3.35, 4.03) 
34.85 
 
 (58) 
3.95 
(3.72, 4.18) 
13.55 
 
(59) 
2.87 
(2.17, 3.56) 
4.58 
 
 
(59) 
2.87 
(2.17, 3.56) 
28.57 
 
 
   
 
(60) 
2.95 
(2.52, 3.39) 
5.19 
 
 
 
 
  
 
   
 
(63) 
3.00 
(2.43, 3.57) 
4.46 
 
 
 
 
   (63) 
2.90 
(2.33, 3.47) 
9.55 
 
(64) 
3.70 
(3.30, 4.10) 
5.40 
 
 
 
 
  
 
   
 
(66) 
2.60 
(1.94, 3.26) 
4.00 
 
 
 
 
  
 
   
 
(68) 
4.06 
(2.57, 5.55) 
1.93 
 
 
 
 
  
 
   
 
(69) 
3.70 
(3.62, 3.78) 
6.83 
 
 
 
 
   (69) 
3.85 
(3.76, 3.94) 
14.69 
 
 
3.21 
(3.01, 3.40) 
 
 
  
3.20 
(2.68, 3.71) 
 
 
 
 
3.42 
(3.13, 3.70) 
 
 
 Q: 121.6; I2: 83.55%; T: 0.38    Q: 11.81; I2: 83.07%; T: 0.41   Q: 53.83; I2: 85.14%; T: 0.37  
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 Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(31) 2.90 (2.13, 3.67) 10.14  3.14 (2.33, 3.96) 4.61  0.24 (-1.15, 1.63) 3.20 
 
(35) 4.10 (2.96, 5.24) 6.42        
(37) 3.40 (3.09, 3.71) 14.82  3.30 (2.97, 3.63) 25.91  -0.10 (-0.55, 0.35) 28.37 
 
(44) 3.60 (3.27, 3.93) 14.63  3.20 (2.82, 3.58) 19.87  -0.40 (-0.90, 0.10) 23.48 
 
(47) 2.70 (2.07, 3.33) 11.03  3.20 (2.52, 3.88) 6.41  0.50 (-0.46, 1.46) 6.45 
 
(52) 2.60 (2.17, 3.03) 13.32  2.60 (2.25, 2.95) 23.03  0.00 (-0.56, 0.56) 18.53 
 
(58) 3.51 (3.10, 3.91) 13.61  3.71 (3.29, 4.13) 16.36  0.20 (-0.38, 0.78) 17.25 
 
(60) 2.60 (1.99, 3.21) 10.82  3.35 (2.41, 4.29) 3.81  0.75 (-0.72, 2.22) 2.71 
 
(68) 4.06 (2.57, 5.55) 5.20        
 3.20 (2.88, 3.53)   3.20 (3.01, 3.34)   -0.03 (-0.27, 0.21)  
 
 Q: 29.79; I2: 73.15%; T: 0.40  Q:17.89; I2: 66.45%; T: 0.33  Q:5.39; I2: 0.00%; T: 0  
 
Time after treatment 
 0-3 months  0-6 months  3-6 months  0-12 months  6-12 months  0-24 months  12-24 months 
Ref. 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
(44) 
-0.04 
(-0.49, 0.41) 
45.36  
-0.07  
(-0.58, 0.43) 
41.54  
-0.03  
(-0.62, 0.56) 
34.98  
-0.13  
(-0.52, 0.27) 
56.69  
-0.06  
(-0.61, 0.50) 
42.59  
-0.44  
(-0.84, -0.05) 
51.95  
-0.31  
(-0.75, 0.12) 
57.15 
(58) 
-0.21 
(-0.62, 0.20) 
54.64  
0.01  
(-0.42, 0.44) 
58.46  
0.23  
(-0.20, 0.65) 
65.02  
0.18  
(-0.27, 0.64) 
43.31  
0.17  
(-0.31, 0.65) 
57.41  
0.09  
(-0.36, 0.53) 
48.05  
-0.10  
(-0.60, 0.40) 
42.85 
 
-0.14 
(-0.44, 0.17) 
  
-0.02  
(-0.35, 0.30) 
  
0.14  
(-0.21, 0.48) 
  
0.01  
(-0.30, 0.31) 
  
0.07  
(-0.29, 0.43) 
  
-0.19  
(-0.71, 0.33) 
  
0.07  
(-0.55, 0.10) 
 
  Q:0.30; I2: 0.00%; T: 0  Q:0.06; I2: 0.00%; T: 0  Q:0.48; I2: 0.00%; T: 0  Q: 1.04; I2: 3.50%; T: 0.04  Q: 0.38; I2: 0.00%; T: 0  Q: 3.05; I2: 67.17%; T: 0.31  Q: 0.41; I2: 0.00%; T: 0 
 
 At diagnosis, before treatment  After treatment  Controls 
PM 
% Ref. 
Mean 
(95% CI) 
Weight 
% 
 
 Ref. 
Mean 
 (95% CI) 
Weight 
% 
 
 Ref. 
Mean 
 (95% CI) 
Weight 
% 
 
(37) 
31.10 
(28.85, 33.35) 
6.78 
 
 
    
 
   
 
(42) 
56.80 
(45.71, 67.89) 
4.19 
 
 
(42) 
49.60 
(41.40, 57.80) 
17.71 
 
 
   
 
(43) 
32.80 
(20.81, 44.79) 
4.09 
 
 
    
 
   
 
(44) 
32.52 
(30.01, 35.02) 
6.73 
 
 
(44) 
40.27 
(37.40, 43.14) 
42.86 
 
 
   
 
(45) 
60.00 
(53.92, 66.08) 
5.69 
 
     
 
   
 
(47) 
59.54 
(54.73, 64.35) 
6.11 
 
     
 
(47) 
66.30 
(63.52, 69.09) 
24.66 
 
(48) 
44.90 
(40.29, 49.51) 
6.17 
 
 
        
 
(51) 
41.80 
(36.52, 47.08) 
5.97 
 
 
    
 
(51) 
61.30 
(59.85, 62.75) 
25.10 
 
(52) 
54.98 
(50.88, 59.08) 
6.32 
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(53) 
36.80 
(31.35, 42.25) 
5.91 
 
 
    
 
   
 
(55) 
36.67 
(35.64, 37.70) 
6.95 
 
 
    
 
   
 
(58) 
42.15 
(39.71, 44.59) 
6.74 
 
 
(58) 
41.05 
(37.71, 44.40) 
39.43 
 
 
(58) 
43.05 
(41.38, 44.71) 
25.03 
 
(60) 
41.03 
(31.23, 50.84) 
4.31 
 
 
    
 
   
 
(61) 
46.26 
(43.75, 48.78) 
6.72 
 
 
    
 
   
 
(65) 
48.45 
(38.57, 58.33) 
4.47 
 
 
    
 
   
 
(66) 
31.70 
(26.13, 37.28) 
5.89 
 
 
    
 
   
 
(69) 
43.00 
42.23, 43.77) 
6.97 
 
 
    
 
(69) 
63.12 
(62.48, 63.75) 
25.22 
 
 
43.28 
(40.03, 46.53) 
 
 
  
42.23 
(38.45, 46.01) 
 
 
 
 
58.42 
(49.62, 67.22) 
 
 
 Q: 407.72; I2: 96.08%; T: 6.27    Q: 5.31; I2: 62.36%; T: 2.57    Q: 510.17; I2: 99.41%; T: 8.93  
 
 Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(37) 34.10 (31.15, 37.05) 15.56  27.69  (24.31, 31.07) 15.41  -6.41  (-10.85, -1.97) 25.80 
 
(44) 33.20 (29.94, 36.46) 15.49   31.60 (27.60, 35.60) 15.25  -1.60  (-6.68, 3.48) 19.82 
 
(47) 62.80 (55.91, 69.69) 14.30  57.40 (50.63, 64.17) 14.32  -5.40  (-15.21, 4.41) 5.51 
 
(52) 56.30 (49.67, 62.94) 14.31  54.20  (48.86, 59.54) 14.81  -2.10  (-10.62, 6.42) 14.81 
 
(58) 42.39 (38.83, 45.95) 15.41  41.71  (38.44, 44.98) 15.44  -0.68  (-5.53, 4.18) 15.44 
 
(61) 48.80 (45.03, 52.57) 15.34  44.50  (41.14, 47.86) 15.41  -4.30  (-9.39, 0.79) 15.41 
 
(60) 39.50 (23.75, 55.25) 9.59  49.50  (31.31, 67.69) 9.37  10.00 (-27.45, 47.45) 9.37 
 
 45.29 (37.68, 52.90)   43.26  (35.37, 51.16)   -3.37  (-5.62, -1.13)  
 
 Q: 127.50; I2: 95.29%; T: 9.73  Q:135.01; I2: 95.56%; T: 10.12  Q:4.39; I2: 0.00%; T: 0  
 
Time after treatment 
 0-3 months  0-6 months  3-6 months  0-12 months  6-12 months  0-24 months  12-24 months 
Ref 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
 
Mean  
(95% CI) 
Weight 
% 
(44) 
-16.95  
(-21.53, -12.38) 
49.42  
-17.17 
(-22.41, -11.93) 
47.11  
-0.22   
(-6.29, 5.86) 
44.57  
-2.43  
(-6.50, 1.63) 
51.95  
14.74  
(8.93, 20.54) 
48.37  
7.75 
(3.72, 11.79) 
49.98  
10.19  
(5.75, 14.62) 
51.05 
(58) 
-14.55 
(-19.07, -10.02) 
50.58  
-10.89  
(-15.2, -6.58) 
52.89  
3.66  
 (-1.77, 9.08) 
55.43  
-3.50  
(-7.73, 0.74) 
48.05  
7.39  
(2.22, 12.56) 
51.63  
-1.10 
(-5.12, 2.92) 
50.02  
2.40  
(-2.56, 7.36) 
48.95 
 
-15.74 
(-18.94, -12.53) 
  
-13.85  
(-19.99, -7.70) 
  
1.93   
(-2.08, 5.95) 
  
-2.94  
(-5.86, 0.03) 
  
10.95  
(3.75, 18.14) 
  
3.33  
(-5.35, 12.00) 
  
6.38  
(-1.26, 14.01) 
 
  Q:0.54; I2: 0.00%; T: 0  Q:3.33; I2: 69.94%; T: 3.72  Q:0.88; I2: 0.00%; T: 0  Q: 0.13; I2: 0.00%; T: 0  Q: 3.48; I2: 71.26%; T: 4.38  Q: 9.38; I2: 81.23%; T: 5.92  Q: 5.33; I2: 81.23%; T: 4.96 
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 At diagnosis, before treatment  After treatment  Controls 
TM 
% Ref. Mean (95% CI) 
Weight 
% 
 Ref. Mean (95% CI) 
Weight 
% 
 
 Ref. Mean (95% CI) 
Weight 
% 
 
(28) 
47.50  
(41.30, 53.70) 
8.62       (28) 
68.80 
(65.03, 72.57) 
20.80 
 
(30) 
59.40  
(50.41, 68.39) 
8.18          
 
   
 
 (34) 
35.20 
(25.29, 45.11) 
34.76 
 
 (34) 
60.90 
(58.23, 63.57) 
22.42 
 
(35) 
35.20  
(20.71, 49.69) 
6.28       (35) 
60.60 
(58.20, 63.00) 
22.82 
 
(36) 
47.40  
(37.35, 57.45) 
7.50       (36) 
71.90 
(65.30, 78.50) 
16.20 
 
(40) 
55.30 
(47.75, 62.85) 
8.25          
 
(48) 
58.02 
(54.01, 62.03) 
9.19          
 
(57) 
35.70 
(25.47, 45.93) 
7.49          
 
(59) 
34.33 
(16.91, 51.75) 
6.15  (59) 
14.83 
(-8.00, 37.67) 
24.60 
 
    
 
(63) 
51.95 
(44.81, 59.09) 
8.36       (63) 
60.48 
(55.22, 65.74) 
17.77 
 
(64) 
32.50 
(26.21, 38.79) 
8.60          
 
(65) 
63.55 
(52.40, 74.70) 
7.14          
 
(67) 
42.20 
(39.95, 44.45) 
9.50  (67) 
44.90 
(42.42, 47.39) 
40.64 
 
    
 
(68) 
47.00 
(24.68, 69.32) 
4.75          
 
 
47.71 
(42.97, 52.46) 
   
34.13 
(20.53, 47.74) 
 
 
  
61.81 
(56.48, 67.13) 
 
 
 Q: 108.64; I2: 88.95%; T: 8.98    Q: 14.83; I2: 86.51%; T: 10.82    Q: 70.22; I2: 92.88%; T: 6.34  
 
 Seminoma 
Ref. Mean (95% CI) Weight % 
(30) 53.80 (12.42, 95.18) 13.78 
(35) 23.80 (9.95, 37.65) 43.44 
(68) 15.29 (-0.48, 31.05) 42.78 
 24.29 (9.91, 38.67)  
  Q: 4.47; I2: 55.23%; T: 6.68 
 
 At diagnosis, before treatment 
VIT 
% Ref. Mean (95% CI) Weight % 
 
(30) 
64.00 
(55.49, 72.51) 
23.71 
 
(58) 
67.44 
(64.99, 69.88) 
26.17 
 
(60) 
71.69 
(67.83, 75.55) 
25.64 
 
(66) 
42.20 
(36.04, 48.36) 
24.49 
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61.53 
(51.00, 72.06) 
 
 
 Q: 72.26; I2: 95.85%; T: 10.43  
 
 Seminoma  Nonseminoma  Difference 
 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(30) 64.00 (55.49, 72.51) 16.50        
(58) 66.98 (63.33, 70.62) 64.06  67.85 (64.72, 70.98) 56.15  0.87 (-3.08, 5.73) 91.20 
 
(60) 68.50 (61.89, 75.11) 19.44  77.00 (69.28, 84.72) 43.85  8.50 (-7.21, 24.21) 8.80 
 
 66.78 (63.92, 69.65)   71.86 (62.96, 80.76)   1.54 (-3.05, 6.14)  
 
 
 Q: 0.88; I2: 0.00%; T: 0  Q: 5.51; I2: 81.85%; T: 5.85  Q: 0.85; I2: 0.00%; T: 0  
 
 At diagnosis, before treatment  Controls 
sSM 
% Ref. Mean (95% CI) Weight %  Ref. Mean (95% CI) Weight % 
     (34) 45.70 (43.81, 47.59) 33.32 
(35) 22.00 (12.28, 31.72) 8.46  (35) 46.30 (44.49, 48.11) 33.32 
(39) 16.20 (13.00, 19.40) 10.13      
(47) 10.40 (8.99, 11.80) 10.34  (47) 13.10 (11.96, 14.24) 33.36 
(48) 3.30 (2.70, 3.90) 10.39     
 
(52) 8.87 (7.91, 9.82) 10.37     
 
(53) 12.81 (8.96, 16.66) 9.98     
 
(61) 20.34 (18.78, 21.91) 10.32     
 
(65) 24.50 (19.14, 29.86) 9.66     
 
(66) 12.70 (8.85, 16.55) 9.98     
 
(67) 24.90 (23.78, 26.02) 10.36     
 
 15.43 (9.60, 21.27)    35.02 (10.86, 59.19)  
 Q: 1418.7; I2: 99.37%; T: 9.23    Q: 1452.9; I2: 99.86%; T: 21.34  
 
 Seminoma  Non-seminoma  Difference 
 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(35) 22.00 (12.28, 31.72) 17.28        
(47) 11.00 (9.02, 12.98) 27.72  10.00  (7.98, 12.02) 33.14  -1.00  (-3.89, 1.89) 25.59 
 
(52) 10.00 (8.43, 11.57) 27.98  8.20  (6.99, 9.41) 33.74  -1.80 (-3.76, 0.16) 54.22 
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(61) 21.70 (19.12, 24.28) 27.02  19.40  (17.42, 21.38) 33.11  -2.30 (-5.48, 0.88) 20.20 
 
 15.51 (9.78, 21.24)   12.51 (5.94, 19.07)   -1.70 (-3.12, -0.27)  
 
  Q: 67.72; I2: 95.57%; T: 5.47  Q: 93.01; I2: 97.85%; T: 5.74  Q: 0.39; I2: 0.00%; T: 0  
 
 At diagnosis, before treatment 
nsSM 
% Ref. Mean (95% CI) Weight % 
 
(30) 19.00 (6.94, 31.06) 12.23 
 
(37) 33.90 (31.69, 36.11) 18.12 
 
(40) 46.10 (44.91, 47.29) 18.44 
 
(42) 38.00 (30.03, 45.97) 14.61 
 
(44) 34.46 (32.19, 36.72) 18.09 
 
(69) 34.00 (33.23, 34.77) 18.51 
 
 35.05 (29.07, 41.03) 
 
 
 Q: 165.98; I2: 97.59%; T: 8.10  
 
  Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(30) 19.00 (6.94, 31.06) 20.26        
(37) 37.50 (34.53, 40.47) 40.18 
 
29.86  (26.69, 33.03) 49.71  -7.64  (-11.96, -3.32) 50.97 
 
(44) 35.40 (32.18, 38.62) 39.56 
 
33.20  (30.05, 36.35) 50.29  -2.20  (-6.78, 2.38) 49.03 
 
 32.92 (26.81, 39.03)   31.54 (28.27, 34.81)   -4.97  (-10.30, 0.36)  
 
  Q: 12.19; I2: 83.60%; T: 4.68  Q: 2.21; I2: 54.77%; T: 1.75  Q: 2.91; I2: 65.58%; T: 3.12  
nsSM, non-strict sperm morphology; PM, sperm progressive motility; SC, sperm concentration; sSM, strict sperm morphology; TSC, total sperm concetration; TM, total sperm motility; V, sperm volume; VIT, vitality.  
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Effects on sperm chromatin structure 
Sperm chromatin is a highly complex but organized structure. The routine analysis of semen 
does not detect defects in this structure.  However, the normal sperm chromatin structure is 
important for sperm fertilizing ability as any form of sperm DNA damage may result in male 
infertility (71).  Moreover, whether sperm DNA damage is augmented in men with cancer 
remains controversial (72, 73). 
To determine the influence of TC on the risk of the sperm genetic damage, were included 
in this meta-analysis 5 studies that assessed SCS on patients with TC before treatment (n=379) 
and 3 studies that assessed SCS in men without TC (n=312). The results of the present meta-
analysis indicate that SCS is statistically significantly higher (p = 0.0032) among men who suffer 
from TC (Mean: 18.46, 95% CI: 13.27, 23.64). This effect is observed among studies that 
involved patients identified only with TC without discriminating among seminoma and 
nonseminoma (Table 3). 
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Table 3. Sperm chromatin structure in testicular cancer patients. 
Patients  Controls 
Ref Mean (95% CI) Weight % 
 
Ref Mean (95% CI) Weight % 
(46) 34.04 (27.44, 40.64) 16.57    
(51) 17.80  (13.36, 22.24) 19.20 (51) 9.00 (7.13, 10.87) 31.79 
(58) 17.10 (15.38, 18.82) 21.61 (58) 11.40 (10.47, 12.33) 42.99 
(63) 8.73 (6.41, 11.05) 21.25 (63) 9.88 (7.50, 12.26) 25.22 
(67) 18.00 (15.90, 20.10) 21.37    
 18.46 (13.27, 23.64)   10.25 (8.61, 11.90)  
 Q: 77.03; I2: 94.81%; T: 5.62   Q: 6.26; I2: 68.04%; T: 1.19  
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Effects on reproductive hormonal characteristics of patients 
Normal spermatogenesis depends on appropriate hormonal secretion of FSH and LH by the 
pituitary, and of testosterone by the testis (74). These are key hormones in male fertility health as 
FSH will influence sperm production, LH will affect the production of testosterone, which in 
turn will act on the Sertoli cell and stimulate spermatogenesis. 
To determine the influence of TC on the regulation of reproductive hormones, 5 studies 
were included that assessed FSH (n = 432), LH (n = 425) and TT (n = 425) on patients with TC 
before treatment; 3 studies that assessed FSH, LH and TT (n = 154 for each hormone) on 
patients presenting seminoma before treatment; 3 studies that assessed FSH, LH and TT (n = 198 
for each hormone) on patients presenting nonseminoma before treatment; 3 studies that 
determined the difference between seminoma (n = 154) and nonseminoma (n = 198) for FSH, 
LH and TT before treatment; 5 studies that assessed FSH (n = 778) and LH (n = 1700), and 4 
studies that assessed TT (n = 1673) on patients after treatment (> 12 months); and 2 studies that 
assessed FSH for 24 months. We observed that while FSH (p = 0.042) and LH (p < 0.0001) are 
statistically significantly increased after treatment, TT (p = 0.0346) is statistically significantly 
decreased. For TT, when differences are determined in relation to controls no difference is noted 
(p = 0.1492). When the TC is discriminated between seminoma and nonseminona, it is noticed 
that, before treatment, non-seminoma patients feature significantly lower FSH values (p < 
0.0001) than seminoma patients. No statistical difference between seminoma and nonseminoma 
patients is observed when LH values are analysed. In relation to TT, it is significantly higher (p = 
0.0057) in nonseminoma. Moreover, when prospective studies were analysed it is observed an 
increase of FSH up to 6 months after treatment, and that after this period and up to 24 months it 
remains stable (Table 4). 
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Table 4. Hormonal profile in testicular cancer patients. 
 At diagnosis, before treatment  After treatment 
FSH  
IU/L Ref. Mean (95% CI) Weight %  Ref. Mean (95% CI) Weight % 
(32) 11.70 (9.10, 14.30) 17.48      
(33) 7.79 (7.53, 8.05) 25.00  (33) 18.80 (16.97, 20.63) 21.89 
   
 
 (41) 22.25 (11.62, 32.88) 14.96 
   
 
 (54) 16.40 (15.36, 17.44) 22.18 
     (56) 5.00 (3.38, 6.62) 22.01 
(57) 11.20 (6.42, 15.98) 10.85  (61) 11.53 (5.98, 17.09) 19.00 
(61) 7.73 (7.00, 8.46) 24.25      
(65) 2.34 (0.96, 3.72) 22.4      
 7.61 (5.67, 9.54)    14.37 (8.16, 20.57)  
 Q:74.35; I2: 94.61%; T: 1.97    Q:181.31; I2: 97.79%; T: 6.70  
 
 Seminoma  Non-seminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
(32) 14.60 (9.50, 19.70) 28.01  10.40 (7.49, 13.31) 30.62  -4.20 (-10.70, 2.30) 3.92 
(61) 9.50 (8.51, 10.49) 37.09  6.50 (5.51, 7.49) 35.57  -3.00 (-4.44, -1.56) 76.91 
(65) 3.28 (0.73, 5.83) 34.89  2.13 (0.27, 3.99) 33.81  -1.15 (-4.12, 1.82) 19.18 
 8.76 (3.62, 13.89)   6.22 (2.42, 10.02)   -2.69 (-3.95, -1.44)  
 Q:28.84; I2: 93.07%; T: 4.27  Q:29.50; I2: 93.22%; T: 3.21  Q:1.51; I2: 0.00%; T: 0  
 
Time after treatment 
 0-6 months  0-12 months  6-12 months  0-24 months  12-24 months 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
(33) 16.61 (15.96, 17.27) 53.60  12.71 (12.04, 13.38) 53.30  -3.90 (-4.86, -2.94) 94.30  9.21 (8.56, 9.86) 76.20  -3.50 (-4.46, -2.54) 95.80 
(61) 10.83 (7.72, 13.94) 46.40  7.94 (5.43, 10.45) 46.70  -2.88 (-6.75, 0.98) 5.70  6.51 (2.62, 10.40) 23.80  -1.43 (-5.94, 3.08) 4.20 
 13.93 (8.27, 19.58)   10.49 (5.82, 15.15)   -3.84 (-4.76, -2.93)   8.57 (6.31, 10.82)   -3.41 (-4.34, -2.49)  
  Q:12.80; I2: 92.19%; T: 3.93     Q: 0.25; I2: 0.00%; T: 0  Q: 1.81; I2: 44.71%; T: 1.28  Q: 0.78; I2: 0.00%; T: 0 
 
 At diagnosis, before treatment  After treatment 
LH  
UI/L Ref. Mean (95% CI) 
Weight 
% 
 Ref. 
Mean 
(95% CI) 
Weight % 
(29) 35.00 (11.39, 58.61) 0.13      
(32) 12.30 (3.71, 20.89) 0.74      
(33) 3.45 (3.35, 3.55) 43.99  (33) 5.78 (5.23, 6.33) 24.05 
     (38) 5.20 (3.75, 6.65) 15.28 
24 
 
     (41) 6.70 (3.98, 9.42) 8.98 
     (54) 8.20 (7.79, 8.61) 25.12 
(61) 3.75 (3.37, 4.14) 39.55      
     (56) 7.00 (6.92, 7.08) 26.6 
(65) 5.16 (3.62, 6.70) 15.6      
 3.94 (3.21, 4.67)    6.71 (5.84, 7.57)  
 Q:20.53; I2: 80.52%; T: 0.56    Q:57.69; I2: 93.07%; T: 0.86  
 
 Seminoma  Nonseminoma  Difference 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
(32) 6.70 (5.27, 8.13) 33.78  14.2 (-3.48, 31.88) 0.65  7.50 (-6.68, 21.68) 0.88 
(61) 3.40 (3.00, 3.80) 36.83  4.00 (3.41, 4.59) 72.98  0.60 (-0.18, 1.38) 84.61 
(65) 6.70 (4.25, 9.15) 29.38  5.38 (3.07, 7.69) 26.38  -1.32 (-4.65, 2.01) 14.51 
 5.48 (2.83, 8.14)   4.43 (3.09, 5.77)   0.38 (-0.92, 1.69)  
  Q:27.50; I2: 92.73%; T: 2.22  Q:2.86; I2: 29.96%; T: 0.74  Q: 2.27; I2: 11.97%; T: 0.61  
 
 At diagnosis, before treatment  After treatment  Controls 
TT 
nmol/L Ref. Mean (95% CI) 
Weight 
% 
 Ref. Mean (95% CI) 
Weight 
% 
 
 Ref. Mean (95% CI) 
Weight 
% 
 
(29) 
18.20  
(12.05, 24.35) 
4.09     
 
     
(32) 
20.10  
(17.30, 22.90) 
12.37     
 
     
(33) 
18.60  
(18.26, 18.94) 
43.95  (33) 
18.10  
(17.25, 18.95) 
25.66 
 
    
 
   
 
 (38) 
16.90  
(15.05, 18.75) 
24.03 
 
 (38) 
17.10  
(14.41, 19.79) 
19.71 
 
   
 
 (41) 
13.45  
(11.88, 15.02) 
24.96 
 
    
 
(61) 
17.72  
(16.72, 18.71) 
33.77     
 
    
 
   
 
 (63) 
12.10  
(11.00, 13.20) 
25.35 
 
    
 
(65) 
24.10  
(19.57, 28.63) 
5.8     
 
 (65) 
17.70  
(16.33, 19.07) 
80.29 
 
 
18.79  
(17.66, 19.92) 
   
15.13  
(11.93, 18.33) 
 
 
  
17.58  
(16.39, 18.77) 
 
 
 Q:10.19; I2: 60.76%; T: 0.85    Q:84.53; I2: 96.45%; T: 3.19    Q:0.16; I2: 0.00%; T: 0  
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 Seminoma  Nonseminoma  Difference 
 
Ref. Mean (95% CI) Weight %  Mean (95% CI) Weight %  Mean (95% CI) Weight % 
 
(32) 19.10 (16.25, 21.96) 33.33  22.5 (18.13, 26.87) 32.17  3.40 (-1.46, 8.26) 14.47 
 
(61) 16.30 (14.91, 17.68) 39.96  18.70 (17.32, 20.08) 47.74  2.40 (0.39, 4.41) 81.28 
 
(65) 22.50 (18.13, 26.88) 26.71  25.40 (18.31, 32.49) 20.09  2.90 (-6.18, 11.98) 4.25 
 
 18.89 (15.52, 22.26)   21.27 (17.41, 25.12)   2.57 (0.76, 4.37)  
 
 
 Q:10.19; I2: 80.37%; T: 2.63  Q:10.19; I2: 80.37%; T: 2.63  Q: 0.15; I2: 0.00%; T: 0  
FSH, follicle stimulating hormone; LH –  luteinizing hormone; TT – total testosterone. 
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Impact of radiotherapy and chemotherapy on fertility 
Both chemo- and radiotherapy can be adopted to treat TC patients, and presently Bleomycin, 
Etoposide and Cisplatin (BEP) regimen is the most commonly used (2). We were able to conduct 
an evaluation of the evolution of four seminal parameters (V, SC, TSC and PM) over follow-up 
by treatment. In terms of V, there are some significant variations, with radio having a lower 
trend, but they are no statistically significant. Regarding SC, both treatments, radiotherapy (p = 
0.0004) and BEP (p < 0.0001), significantly reduce SC up until 12 months. 24 months after 
treatment, while radiotherapy patients return to get diagnostic levels of SC, the BEP patients 
present a statistically significant higher SC (p = 0.0004). There were no statistically significant 
fluctuations between the reductions of SC among the two treatments. In terms of TSC the picture 
is different from the SC. Radiotherapy and BEP present a similar effect trend over TSC up to 12 
months. Though, radiotherapy treated patients reacquire TSC levels at diagnostic only at 24 
months while BEP treated patients at 12 months. At 24 months, TSC in BEP treated patients is 
higher than at diagnosis (p=0.0014). PM is decreased in the first 6 months after treatment for 
both radiotherapy (p<0.0001) and BEP (p<0.0001) and returns to diagnostic levels at 12 months. 
The initial decrease of PM is steeper for BEP than for radiotherapy (p = 0.0032). 
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Table 5. Semen parameters evaluated for testicular cancer patients with BEP regimen or radiotherapy (RT). 
 References 0-3 months 0-6 months 0-12 months 0-24 months 
V 
mL 
 
BEP 
 Mean (95% CI) Weight % Mean (95% CI) Weight % Mean (95% CI) Weight % Mean (95% CI) Weight % 
(44) 0.50 (-0.25, 1.25) 42.99 0.40 (-0.37, 1.17) 39.47 0.10 (-0.51, 0.71) 51.87 0.10 (-1.30, -0.30) 48.73 
(58) -0.16 (-0.73, 0.40) 57.01 0.20 (-0.42, 0.82) 60.53 -0.09 (-0.73, 0.54) 48.13 0.17 (-0.64, 0.66) 51.27 
 0.12 (-0.52, 0.76)  0.28 (-0.20, 0.75)  0.01 (-0.43, 0.44)  0.14 (-0.30, 0.58)  
  Q: 1.95, I2: 48.68%, T: 0.33 Q: 0.17, I2: 0.00%, T: 0 Q: 0.19, I2: 0.00%, T: 0 Q: 0.03, I2: 0.00%, T: 0 
 
RT (44) -0.40 (-0.97, 0.17) 52.92 -0.40 (-1.08, 0.28) 43.84 -0.30 (-0.83, 0.23) 54.86 -0.80 (-1.30, -0.30) 53.15 
(58) -0.26 (-0.86, 0.34) 47.08 -0.15 (-0.75, 0.45) 56.06 0.40 (-0.25, 1.05) 46.14 0.01 (-0.64, 0.66) 46.85 
 -0.33 (-0.74, 0.07)  -0.26 (-0.71, 0.19)  0.02 (-0.66, 0.71)  -0.42 (-1.21, 0.37)  
   Q: 0.11 ,I2: 0.00%, T: 0 Q: 0.30, I2: 0.00%, T: 0 Q: 2.72, I2: 63.29%, T: 0.39 Q: 3.82, I2: 73.81%, T: 0.49 
 
SC 
106/mL 
BEP (44) -24.20 (-33.61, -14.79) 34.70 -19.70 (-30.23, -9.17) 29.79 -4.30 (-12.82, 4.22) 35.44 25.00 (11.98, 38.02) 35.80 
(58) -24.23 (-31.08, -17.38) 65.30 -18.85 (-26.72, -10.97) 53.01 -10.60 (-20.09, -1.10) 32.13 5.75 (-4.43, 15.92) 41.21 
(61)   -13.60 (-27.33, 0.13) 17.19 -17.60 (-26.93, -8.27) 32.43 9.70 (-11.34, 30.74) 22.98 
 -24.22 (-29.69, -18.75)  -18.20 (-23.87, -12.53)  -10.64 (-18.30, -2.98)  13.55 (0.30, 26.8)  
  Q: 0.00, I2: 0.00%, T: 0 Q: 0.54, I2: 0.00%, T: 0 Q: 4.32, I2: 53.69%, T: 4.96 Q: 5.43, I2: 63.17%, T: 9.2 
 
RT (30) -34.10 (-93.76, 25.56) 1.98 -41.10 (-98.44, 16.24) 2.71 49.68 (-61.77, 161.12) 0.48   
(44) -24.90 (-35.81, -13.99) 46.73 -26.50 (-38.82, -14.18) 34.93 -14.00 (-23.83, -4.17) 48.30 8.50 (-3.12, 20.12) 49.63 
(58) -25.34 (-35.76, -14.92) 51.29 -24.35 (-36.01, -12.69) 37.87 -14.47 (-25.68, -3.26) 37.31 0.88 (-12.96, -14.72) 35.12 
(61)   -9.80 (-25.22, 5.62) 24.48 -2.20 (-20.47, 16.07) 13.92 8.00 (-12.90, 28.90) 15.25 
 -25.31 (-32.7, -17.92)  -21.99 (-30.39, -13.60)  -12.23 (-19.01, -5.45)  5.75(-2.37, 13.86)  
   Q: 0.11, I2: 0.00%, T: 0 Q: 3.66, I2: 18.07%, T: 3.71 Q: 2.99, I2: 0.00%, T: 0 Q: 0.75, I2: 0.00%, T: 0 
 
TSC 
106 
BEP (44) -72.70 (-104.1, -41.30) 46.73 -60.00 (-94.97, -25.03) 49.52 -13.90 (-42.21, -14.41) 55.85 63.20 (26.85, 99.55) 55.07 
(58) -88.29 (-117.66, -58.93) 53.27 -64.80 (-99.35, -30.25) 50.48 -44.61 (-79.78, -9.44) 44.15 24.02 (-19.97, 68.00) 44.93 
 -81.01 (-102.20, -59.82)  -62.42 (-86.70, -38.14)  -27.46 (-57.35, 2.43)  45.60 (7.39, 83.80)  
  Q: 0.52, I2: 0.00%, T: 0 Q: 0.04, I2: 0.00%, T: 0 Q: 1.82, I2: 45.02%, T: 14.6 Q: 1.86, I2: 46.12%, T: 18.80 
 
RT (44) -85.90 (-121.16, 50.64) 64.38 -90.80 (-130.52, -51.08) 66.31 -48.90 (-81.59, -16.21) 71.33 -4.70 (-38.59, 29.19) 76.53 
(58) -94.01 (-141.46, -46.56) 35.62 -87.45 (-143.17, -31.73) 33.69 -50.87 (-102.54, 0.80) 28.67 0.13 (-61.22, 61.48) 23.47 
 -88.79 (-116.83, -60.75)  -89.67 (-121.70, -57.64)  -49.46 (-76.86, -22.07)  -3.57 (-32.97, 25.83)  
   Q: 0.07, I2: 0.00%, T: 0 Q: Q: 0.01, I2: 0.00%, T: 0 Q: 0.00, I2: 0.00%, T: 0 Q: 0.02, I2: 0.00%, T: 0 
 
PM 
% 
BEP (44) -19.80 (-27.17, -12.43) 45.45 -17.10 (-25.50, -8.70) 37.54 0.80 (-5.66, 7.26) 50.01 9.80 (3.01, 16.59) 50.52 
(58) -22.46 (-29.18, -15.75) 54.55 -11.60 (-17.97, -5.23) 62.46 -6.68 (-13.14, -0.21) 49.99 0.78 (-5.32, 6.88) 49.48 
 -21.25 (-26.16, -16.35)  -13.66 (-18.89, -8.44)  -2.94 (-10.27, 4.39)  5.16 (-3.67, 14.00)  
  Q: 0.28, I2: 0.00%, T: 0 Q: Q: 1.07, I2: 6.85%, T: 1.02 Q: 2.63, I2: 62.01%, T: 4.16 Q: 6.02, I2: 74.02%, T: 5.49 
 
Radio (44) -15.40 (-21.30, -9.50) 48.90 -17.30 (-24.12, -10.48) 46.95 -4.70 (-9.98, 0.58) 51.68 6.40 (1.34, 11.46) 50.52 
(58) -8.11 (-13.61, -2.61) 51.10 -10.28 (-16.17, -4.39) 53.05 -1.08 (-6.55, 4.39) 48.32 -2.77 (-8.17, 2.63) 49.48 
 -11.67 (-18.82, -4.53)  -13.58 (-20.44, -6.71)  -2.95 (-6.72, 0.81)  1.86 (-7.12, 10.85)  
   Q: 3.20, I2: 68.74%, T: 4.27 Q: 2.38, I2: 57.97%, T: 3.78 Q: 0.89, I2: 0.00%, T: 0 Q: 6.02, I2: 83.38%, T: 5. 92 
BEP, bleomycin + etoposide + cisplatin regimen; PM, progressive motility; SC, sperm count; TSC, total sperm count; V, sperm volume. 
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DISCUSSION 
The main goal of cancer treatment is to reduce treatment-related long-term toxicities, in which 
sub/infertility may be included. Concerning male patients, sperm banking (75) or testicular tissue 
cryopreservation in the case of prepubertal boys (76) should be offered prior the initiation of the 
treatment. In the case of TC, because the organ in question, the preservation of fertility becomes 
a prominent concern. Accordingly to the European Association of Urology testis cancer 
guidelines, among the tests for staging at diagnosis and follow-up schedules after treatment 
recommended are fertility investigations, which include FSH, LH, TT and semen analyses (77). 
We have, therefore, evaluated in the present meta-analysis these outcomes along with sperm 
genomic integrity among men with TC both at diagnosis and after treatment.  
Regarding the age of patients, our results demonstrate that TC affects young males, and 
are in agreement with the peaks of incidence at 25 (26.32 ± 5.32) and 35 (30.17 ± 5.70) for 
nonseminoma and seminoma tumors, respectively (78). An increase in average of paternal age is 
a direct consequence of human reproductive behavior (79).  Although the effect of male age is 
less prominent than of the female, our results suggest that TC patients’ age becomes significant 
since TC diagnostic is at their fertility potential peak (80), patients have to delay their fatherhood 
planning, and as TC survivors present reduced paternity (81).  
Standard seminal parameters are routinely used as an indirect measure of male fertility 
(82). A decrease trend in TC semen characteristics is apparent comparing to matched controls, 
though these are above the WHO lower reference limits. Since no alterations are observed in 
TC’s V, this may indicate that reproductive accessory glands are not affected. In terms of 
motility, we found that TM was the only parameter affected beyond the WHO lower reference 
limit after the treatment, and in seminoma patients. Strangely, TM is inferior to PM. Another, 
peculiar finding is a substantial increase of TSC after treatment in relation to SC. These results 
may be attributed to measurement errors, a smaller sample studied in TSC after treatment that 
29 
 
may increase bias or to increased volumes in these specific samples. These results are 
contradictory to the hormonal results as it would be expected that the semen parameters were 
most affected. However, when an analysis based on the two histopathological types of TC is 
performed, the aggressiveness of the nonseminoma type is reflected both by a decrease on FSH, 
SC, TSC, PM and SM, and on the other hand an increase on LH and TT. Contradictory results 
may mirror the urgency to adopt a standardized protocol to measure semen parameters. This 
urgency is alarming on the determination of morphology. We have had, indeed, the need to 
separate studies using strict criteria from those using non-strict criteria. Even tough, the 
variability between studies is a huge obstacle that we were not able to disclose if this is due to 
observer variability or in the absence of this it appears that there are other factors affecting sperm 
morphology rather than TC per se or its treatment. Both CT and RT pose a high risk of decreased 
patients’ reproductive potential, still conflicting results about which treatment is more 
detrimental to this potential remain. We have found that patients receiving BEP regimen may 
expect a recovery of semen parameters to values higher than the ones determined at diagnosis 
after 24 months of treatment, while the ones subjected to radiotherapy may only expect similar 
results. Nevertheless, according to the European Association of Urology testis cancer guidelines 
follow-up should at least be ensued once a year up to 5-10 after treatment (77).  Besides, it 
would be of importance to determine if there are differences between patients already presenting 
azoospermia at diagnosis from the ones that are not, and the ones that progress to it. 
Endocrine system is a crucial regulator of organ system functions, and the testes are no 
exception. For long that is recognised that FSH, LH and testosterone regulate spermatogenesis. 
Previous studies indicated that alterations of serum levels of these hormones occur in a 
significant proportion of TC patients at diagnosis and after treatment, irrespective of the 
histological type or oncological treatment strategies adopted (83). Serum hormone levels were 
found to be within the normal range for the majority of patients analysed. Our results agree with 
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those that have already suggested that an elevation of LH concentration and a decrease of 
testosterone concentration are indicative of disturbed Leydig cell function. Moreover, the 
elevated FSH concentrations observed after treatment (almost the double of higher limit of the 
normal range) may also be suggestive of a disturbance of spermatogenesis. This disturbance 
appears to be increased in the first 6 months after treatment and for a period of two years no 
recovery seems to happen. These findings seem to be more expressive for nonseminoma patients 
in the case of LH and TT, and for seminoma ones in the case of FSH. Our results support the 
knowledge that patients with TC have abnormal spermatogenesis, which deteriorates even 
further after treatment. However, recent research has demonstrated that FSH, LH and 
testosterone are not the only hormones regulating spermatogenesis. Therefore, other hormones 
should be measured in future prospective studies as they may be better markers for testicular 
injury. For instance, hormones that reflect the Sertoli cell function, a key player in 
spermatogenesis, such as AMH (Anti-Mullerian Hormone, already used to predict cryptorchism 
a known risk factor for TC, (84)), and thyroid hormones (triiodothyronine, T3 and thyroxin, T4 
(85)). Likewise, hormones that regulate the activity of FSH, LH or testosterone should also be 
studied. For example, inhibin B which controls FSH secretion via a negative feedback (86), is of 
utmost importance. Although undetectable inhibin B levels have been associated with an absence 
of spermatogenic activity (87), Di Bisceglie and colleagues did not found alterations on inhibin 
B levels during two years after treatment, though levels were described to be lower in patients 
treated by CT than by RT (61). Other hormones that may also be studied are prolactin which 
regulates testosterone synthesis on Leydig cells (88), estradiol which regulates both the activity 
of LH and testosterone (89), and β-human Chorionic Gonadotrophin (βhCG) which pathological 
levels were correlated with abnormalities in semen quality of TC patients (37). Tovar-Rodriguez 
and colleagues have also demonstrated that these two latter hormones are increased in TC 
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patients comparing to controls, with nonseminoma presenting increased levels compared with 
the seminoma cases (65).  
Delaying fatherhood is a preoccupation of TC patients, but the impact of their condition 
and treatment that they will be subjected to in the health and well-being of their offspring is 
perhaps more important (90). Several functional tests are being used to measure sperm DNA 
integrity in these patients, yet in the present analysis only studies that evaluated the SCS were 
eligible (46, 51, 58, 63, 67). A progressive decrease of sperm genomic integrity was observed 
from sperm donors to TC patients. We were unable to study the difference among 
histopathological types of TC and among different treatments, specifically CT and RT. 
Regarding the difference between the two TC histological types, only Paoli and colleagues have 
studied it. They found no differences in pre-treatment, but uncovered a significant increase in 
impaired SCS after 3-6 months of treatment with 3-4 CT cycles which was dependent on the 
pathological and clinical stage (67). Concerning the impact of treatment option, results are 
conflicting with few observing that chemotherapy is more injurious to the sperm DNA than 
radiotherapy, and others finding opposite outcomes. Nevertheless, both CT and RT can induce 
other genome alterations like aneuploidy (91), epi- (92) and structural (93) genetic alteration (94, 
95), spermatozoa methylation patterns (96), among others. Although, studies of children of TC 
survivors show no evidence of more frequent abnormalities in offspring (97, 98), we suggest 
counselling of patients about probable risks. Indeed, sperm DNA integrity has already been 
correlated to semen parameters and proved to be reduced either with cell sorting (99) and 
sequential sperm preparation procedures (100), still the mechanism behind it remains unclear. A 
standardized method to determine sperm DNA integrity is also lacking and further detailed 
studies of offspring from patients with cancer are necessary. Additionally, literature regarding 
follow-up is scarce and were not eligible for this study, though no comparisons to post-treatment 
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patients’ sperm genomic integrity were ensued. We thus recommend future prospective studies. 
Meanwhile, patients should be advised to preserve their fertility prior the initiation of treatment.    
In summary, our results point towards a decrease of reproductive potential of TC patients 
which seems to improve on the long run. Nevertheless, the inability to define thresholds for TC 
patients or to find correlations between the parameters evaluated are limitations of this study. 
These limitations arise essentially from the divergences in the previous published studies. 
Incongruities may directly be related to differences in a) characteristics of patients studied 
(number, age, time of abstinence before ejaculate collection, discrimination between patients 
accordingly to their histological type of TC or stage of disease, among others (in)direct-
influenceable); b) antineoplastic treatment adopted and dose; c) parameters evaluated, and 
criteria and methods adopted to assess it (for example cryopreserved samples display abnormal 
parameters (62, 101, 102); d) variances of the follow-up protocols and time of evaluation; and e) 
the selection bias of the controls (it is debatable even in ART programs if comparisons should be 
done against proven fertile patients or population-based controls of age-matched). 
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